Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03112174 · OUTCOME

Complete Response (CR) Rate (Treatment-Naive Arm)

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) · Source last updated 2025-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
For an overall median time on study of 40.51 months

What was measured

CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

Analysis population: All Enrolled Treatment-Naïve Participants

Groups in this outcome

Treatment-naive Open-label Arm

Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment-naive Open-label Arm78

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment-naive Open-label Arm69.2Not reported57.879.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        57.8
        upper Limit
        79.2
        value
        69.2
denoms
  1. counts
    1. group Id
      OG000
      value
      78
    units
    Participants
description
CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).
    id
    OG000
    title
    Treatment-naive Open-label Arm
param Type
NUMBER
population Description
All Enrolled Treatment-Naïve Participants
reporting Status
POSTED
time Frame
For an overall median time on study of 40.51 months
title
Complete Response (CR) Rate (Treatment-Naive Arm)
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice